Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
August 2014—Thermo Fisher Scientific’s refrigerated small benchtop centrifuges separate samples in a compact footprint and run a wide range of applications. The refrigeration system provides a temperature range of -10°C to -40°C and can maintain temperatures when the chamber is not in use.
August 2014—HTG Molecular Diagnostics announced the availability of HTG EdgeSeq miRNA Whole Transcriptome Assay for measuring the expression of 2,275 human microRNAs described in the miRBase v20 database.
August 2014—Ventana Medical Systems launched three robust prototype assays for the detection of biomarkers PSMA (prostate specific membrane antigen), MDM2 (mouse double minute 2), and FGFR (fibroblast growth factor receptor 2).
August 2014—Two veteran public relations consultants, Ryan Fitzgerald and Chuck Weber, have formed Prefix Public Relations, which offers a unique value proposition: clients pay fixed-price fees for ongoing programs and services instead of hourly charges.
August 2014—Streck added markers to CD-Chex CD117 Plus, a commercially available positive procedural control for CD117, and now CD25 and CD71. CD-Chex 117 Plus eliminates the need for laboratories to hold and validate patient samples to use as a control for CD117, CD25, and CD71.
August 2014—Curetis announced that Robin Patel, MD, professor of medicine and microbiology at Mayo Clinic in Rochester, Minn., has been named lead principal investigator of the company’s Unyvero LRT Application FDA trial.
August 2014—Qiagen launched 14 GeneRead DNAseq V2 gene panels targeting a range of cancer-related genes or gene regions, including focused panels, each targeting 8–25 genes, disease-specific panels for 40–50 genes, and comprehensive panels for as many as 160 genes.
August 2014—The Clinical and Laboratory Standards Institute published H52-A2—Red Blood Cell Diagnostic Testing Using Flow Cytometry; Approved Guideline—Second Edition. This standard addresses the diagnostic red blood cell assays performed as fluorescence-based assays on a flow cytometry platform, including testing procedures for fetomaternal hemorrhage detection, paroxysmal nocturnal hematuria screening, membrane defect anemia testing for hereditary spherocytosis, and nucleated RBC counting. Caveats of interpretation and points of validation and quality control are also discussed.
August 2014—Primera’s Signature Cassette Printer prints high-resolution text and graphics along with linear and 2D bar codes directly onto tissue cassettes. The printer has four cassette hoppers, each holding 40 cassettes, and can print up to 11 cassettes per minute.
August 2014—SeraCare Life Sciences released four research panels that deliver hard-to-find material for hepatitis C, Chagas, and dengue.
